Quick Answer
GeneDx Holdings Corp. reported Research And Development Expense of $72.03 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +57.5% in Research And Development Expense from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $13.10 million | Q2 2020: $9.36 million | Q3 2020: $19.08 million | Q4 2020: $31.16 million | Q1 2021: $53.13 million | Q2 2021: $11.95 million | Q3 2021: $17.83 million | Q4 2021: $22.25 million | Q1 2022: $21.32 million | Q2 2022: $27.17 million | Q3 2022: $13.35 million | Q1 2023: $14.59 million | Q2 2023: $17.14 million | Q3 2023: $14.29 million | Q1 2024: $11.57 million | Q2 2024: $10.90 million | Q3 2024: $11.67 million | Q1 2025: $12.58 million | Q2 2025: $15.08 million | Q3 2025: $19.83 million.
- Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Research And Development Expense has grown by 106.3%.
- Historical annual values: Fiscal year 2025: $72.03 million | Fiscal year 2024: $45.72 million | Fiscal year 2023: $58.27 million | Fiscal year 2022: $86.20 million | Fiscal year 2021: $105.16 million | Fiscal year 2020: $72.70 million | Fiscal year 2019: $34.91 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: